Proxalutamide

Proxalutamide
Clinical data
Other names	Pruxelutamide; GT-0918
Routes of; administration	By mouth
Drug class	Nonsteroidal antiandrogen
ATC code	None;
Identifiers
	IUPAC name 4-[4,4-dimethyl-3-[6-[3-(1,3-oxazol-2-yl)propyl]pyridin-3-yl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-fluoro-2-(trifluoromethyl)benzonitrile;
CAS Number	1398046-21-3;
PubChem CID	60194102;
ChemSpider	52084193;
UNII	QX6O64GP40;
CompTox Dashboard (EPA)	DTXSID901102678 ;
Chemical and physical data
Formula	C24H19F4N5O2S
Molar mass	517.50 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(C(=O)N(C(=S)N1C2=CN=C(C=C2)CCCC3=NC=CO3)C4=C(C(=C(C=C4)C#N)C(F)(F)F)F)C;
	InChI InChI=1S/C24H19F4N5O2S/c1-23(2)21(34)32(17-9-6-14(12-29)19(20(17)25)24(26,27)28)22(36)33(23)16-8-7-15(31-13-16)4-3-5-18-30-10-11-35-18/h6-11,13H,3-5H2,1-2H3; Key:KCBJGVDOSBKVKP-UHFFFAOYSA-N;

Proxalutamide (developmental code name GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of COVID-19, prostate cancer, and breast cancer.^[1]^[2]^[3]^[4]^[5] It was approved in Paraguay for the treatment of COVID-19 in July 2021, but has not been approved at this time in other countries.^[1]

Quick facts Clinical data, Other names ...

Research